EMEA-001296-PIP01-12-M04
Key facts
| Invented name |
Adynovi
|
| Active substance |
rurioctocog alfa pegol
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0302/2021
|
| PIP number |
EMEA-001296-PIP01-12-M04
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Baxalta Innovations GmbH
E-mail: medinfoEMEA@takeda.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|